Aditya Kunjapur awarded BII & Science Prize for Innovation 2024 - BioInnovation Institute

Aditya Kunjapur awarded BII & Science Prize for Innovation 2024

Aditya Kunjapur awarded BII & Science Prize for Innovation 2024

This is an official press release originally written and released by Science Magazine and AAAS. 

Bacterial proteins often play a successful hide and seek game with the body’s immune system, making it difficult to combat the bacteria that cause diseases like staph infections.

Biomolecular engineer Aditya Kunjapur and colleagues now have a strategy to create bacteria that build and incorporate a key amino acid into their own proteins, which makes the proteins more “visible” to the immune system.

For this work toward building a better platform for possible future bacterial vaccines, Kunjapur is the winner of the 2024 BioInnovation Institute & Science Prize for Innovation. The prize seeks to reward scientists who deliver research at the intersection of the life sciences and entrepreneurship.

“Dr. Kunjapur’s outstanding research demonstrates the potential to engineer live bacterial cells to produce and incorporate nitrated amino acids into antigenic proteins, thus shining a spotlight on these proteins for the human immune system,” said Michael Funk, senior editor at Science. “This work provides a platform for antigen engineering that is adaptable, specific, and amenable to safety controls.”

Vaccines against bacterial infections would likely decrease the need for antibiotic medicines, which in turn could stem the development of antibiotic resistance in some key drugs. Kunjapur, an assistant professor of chemical and biomolecular engineering at the University of Delaware, said bacterial vaccines will have an estimated global market size of $39.6 billion by 2030.

In his winning essay published April 5 in Science Magazine, Kunjapur writes that “our primary hypothesis is that engineering cells to access a broader chemical repertoire of building blocks can improve live bacterial vaccine efficacy.”

One of the building blocks that caught Kunjapur’s eye came from previous research that modified a bacterial protein with a non-standard amino acid called para-nitro-L-phenylalanine (nitro-Phe). These nitrated proteins triggered sustained production of antibodies in mice, suggesting that the altered amino acid was making it easier for the immune system to access or recognize the bacterial protein.

Kunjapur and colleagues have now programmed E. coli bacterial cells to synthesize their own nitro-Phe and incorporate it into target proteins. These altered proteins could someday become the basis for a live bacterial vaccine, the researchers suggest.

“In principle, the nitro-Phe modified protein produced by the engineered bacteria within a patient would lead to a targeted, sustained, and protective immune response towards bacterial pathogens,” even versions of the protein that haven’t been nitrated, Kunjapur said.

Kunjapur’s research team used E. coli as a proof-of-concept for their bioengineering strategy, but he said the strategy could work with other bacteria as well, including those that might be better at targeting certain pathogens or even tumor tissue.

“We could also continue to use E. coli as a platform vector that makes recombinant proteins that belong to other bacteria,” he said. “So you can pick your chassis or your protein delivery vehicle, but the proteins you choose to nitrate should determine what immune cells respond to.”

“While we have a platform technology with several promising directions, one attractive indication would be a vaccine for staph infections,” Kunjapur added. The need for a staph vaccine was emphasized in meetings Kunjapur’s postdoc Neil Butler held with individuals from pharmaceutical companies, clinical trial operators and hospital staff as part of his participation with the U.S. National Science Foundation Innovation Corps program.

Finding funding for filing intellectual property was a challenge during the years of the pandemic, and Kunjapur used his own funds for his Patent Cooperation Treaty patent application. “At the time I had cautious optimism in investing in new potential vaccine modalities during the height of a pandemic, but a lot of it was also a bet on the people behind the idea and our collaborators,” he said.

Kunjapur co-founded Nitro Biosciences, Inc. with Butler to pursue the nitro-Phe technology. He said starting the company has made him think more about who is going to use the technology, and what kind of criteria and metrics they need to know so that it can be used successfully.

“It’s a shame that a lot of academic work has the potential to make a difference in people’s lives, but academics aren’t ordinarily incentivized or trained to think about what the customer needs, who the customer is, and how do you advance the technology to the stage where it could be in the clinic,” Kunjapur said.

In his lab at the University of Delaware, Kunjapur and his students are also working on other bioengineering projects with environmental applications, including containment strategies “to prevent a genetically modified organism like bacteria from surviving where and when it shouldn’t,” he said.

“This year’s finalists have conducted some truly exceptional research and the standard of all entries was extremely high,” said Jens Nielsen, chief executive officer at BioInnovation Institute. “Their work combines cutting edge science with entrepreneurial spirit, aligning with BII’s goals of improving human and planetary health.”

Sign up for the BII & Science Prize for Innovation Grand Award Ceremony 2024

Read our impact report and get acquainted with the progress that BII experienced during 2022

Read more
Impact Report 2022